These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 3923913

  • 1. Pseudomonas aeruginosa surface polysaccharide vaccines. New therapeutic approaches from basic research.
    Pier GB.
    Antibiot Chemother (1971); 1985; 36():157-67. PubMed ID: 3923913
    [Abstract] [Full Text] [Related]

  • 2. Polysaccharide antigens of Pseudomonas aeruginosa.
    Pier GB.
    Rev Infect Dis; 1988; 10 Suppl 2():S337-40. PubMed ID: 3142017
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody to Pseudomonas aeruginosa.
    Pier GB, Takeda S, Grout M, Markham RB.
    J Clin Invest; 1993 Mar; 91(3):1079-87. PubMed ID: 8450038
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G.
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.
    Theilacker C, Coleman FT, Mueschenborn S, Llosa N, Grout M, Pier GB.
    Infect Immun; 2003 Jul; 71(7):3875-84. PubMed ID: 12819072
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
    Eichler I, Joris L, Hsu YP, Van Wye J, Bram R, Moss R.
    J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330
    [Abstract] [Full Text] [Related]

  • 18. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.
    Pier GB, DesJardin D, Grout M, Garner C, Bennett SE, Pekoe G, Fuller SA, Thornton MO, Harkonen WS, Miller HC.
    Infect Immun; 1994 Sep; 62(9):3972-9. PubMed ID: 8063415
    [Abstract] [Full Text] [Related]

  • 19. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
    Joó I, Stanislavskii ES.
    J Hyg Epidemiol Microbiol Immunol; 1982 Sep; 26(4):417-27. PubMed ID: 6819316
    [Abstract] [Full Text] [Related]

  • 20. The role of cytophilic IgG3 antibody in T cell-mediated resistance to infection with the extracellular bacterium, Pseudomonas aeruginosa.
    Markham RB, Pier GB, Schreiber JR.
    J Immunol; 1991 Jan 01; 146(1):316-20. PubMed ID: 1898604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.